Tags : Boston Scientific

Boston Scientific Receives the US FDA’s 510(k) Clearance for its

Shots: LUX-DxICM System is a dual-stage algorithm diagnostic device implanted in patients to identify AF, atrial flutter, rhythm pause, bradycardia, and tachycardia episodes and detect arrhythmias when established thresholds or parameters are exceeded The dual-stage algorithm verifies arrhythmias before an alert is sent to clinicians, thereby providing actionable data for clinical decision-making. Additionally, after implant, […]Read More

Top 20 Medical Device Companies Based on 2019 Revenue

The Medical device market is growing with evolving needs of patients and with their emerging diseases encouraging them to develop novel and innovative therapies or devices for maintaining quality of life. The ledger for 2019 of medical devices has shown changes for multiple companies but the position for Medtronic remains same to be one top […]Read More

PharmaShots Weekly Snapshot (August 19 – 23, 2019)

OxThera’s Oxabact Receives EMA’s Positive Decision on Pediatric Investigational Plan to Treat Primary Hyperoxaluria Published: Aug 23, 2019 | Tags: OxThera, Oxabact, Receives, EMA, Positive Decision, Pediatric Investigational Plan, Treat, Primary Hyperoxaluria 2.Novartis Signs an Option Agreement with Iconic Therapeutics for its Ophthalmology Program Published: Aug 22, 2019 | Tags: Novartis, Signs, Option Agreement, Iconic Therapeutics, Ophthalmology […]Read More

Top 20 Life Sciences Deals of 2018 Based on Total

Healthcare, pharmaceutical, and biotech companies are gearing up to tap new markets as they look to consolidate their positions after a spate of mergers & acquisitions and licensing partnerships in 2018. The highest valued deal proved to be of Takeda’s acquisition of Shire for $57B with the focus on global R&D, its robust and modality-diverse […]Read More

Varian to Acquire Boston Scientific’s Oncology Assets for $90M

Shots: Varian acquires the Boston Scientific drug-loadable microsphere (Oncozene/Embozene Tandem) and bland embolic (Embozene) bead products for the treatment of arteriovenous malformations and hypervascular tumors for $90M The focus of the acquisition is to expand Varian’s interventional oncology portfolio and to get benefits from the acquired product’s regulatory clearances in 35+ countries globally Varian plans […]Read More

Boston Scientific Initiates OPTION Study of Watchman FLX Device for

Shots: The OPTION study involves assessing of Watchman FLX left atrial appendage closure vs oral anticoagulants (OAC) including direct oral anticoagulants (DOAC) & warfarin in 1,600 patients with non-valvular AF who undergo a cardiac ablation across 130 sites globally The OPTION study will have its 1EPs as all cause death, stroke and systemic embolism with […]Read More

Boston Scientific Reports Results of Emblem S-ICD System in UNTOUCHED

Shots: The UNTOUCHED study involves assessing Emblem Subcutaneous Implantable Defibrillator (S-ICD) system in 1,116 patients with a left ventricular ejection fraction (LVEF) ≤35% + ischemic heart disease The UNTOUCHED study results: complication-free rate (95.8%) @30days post-procedure; induced ventricular fibrillation rates (99.2%); patients performed using a two-incision technique (69%); mean implant time (55.8 mins.) Emblem S-ICD […]Read More

Boston Scientific Acquires BTG with its Interventional Medicine Portfolio

Shots: Boston acquired BTG in all stocks transaction, for ~$1.07/per share at a premium of 36.6%, with total deal value of $4.2B. The transaction is expected to close in H1’19 The acquisition will strengthen Boston’s peripheral intervention platform with BTG’s minimally-invasive treatments like TheraSphere Y-90 radiotherapy, GALI cryoablation and EKOS Endovascular System for treatment of […]Read More